Skye Bioscience, Inc. (SKYE)
- Previous Close
12.85 - Open
13.00 - Bid 12.73 x 100
- Ask 13.36 x 100
- Day's Range
12.68 - 13.08 - 52 Week Range
1.44 - 19.41 - Volume
31,336 - Avg. Volume
44,419 - Market Cap (intraday)
364.818M - Beta (5Y Monthly) 1.71
- PE Ratio (TTM)
-- - EPS (TTM)
-5.37 - Earnings Date May 12, 2024 - May 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.50
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system. The company's lead clinical program's product candidate is nimacimab, a peripherally-restricted negative allosteric modulating antibody specific for the human cannabinoid receptor 1 (CB1) receptor, administered as a subcutaneous injectable that is Phase II clinical trials for the treatment of metabolic disorders, including obesity. It is also developing SBI-100 Ophthalmic Emulsion,a CB1 agonist that is Phase II clinical trials for the treatment of glaucoma and ocular hypertension. It has licensing agreement with Tautomer Bioscience, (Pty) Limited to develop and commercialize SBI-100; and collaborative research agreement with VivaCell Biotechnology Espana, S.L.U for the research and development of SBI-200 and the preclinical development services for novel derivatives. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
skyebioscience.comRecent News: SKYE
Performance Overview: SKYE
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SKYE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SKYE
Valuation Measures
Market Cap
360.61M
Enterprise Value
363.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
87.34
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-9.94
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-80.28%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-37.64M
Diluted EPS (ttm)
-5.37
Balance Sheet and Cash Flow
Total Cash (mrq)
1.38M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-10.91M